PULMONX CORPORATION

LUNG

CIK 0001127537 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$23M
↓-4.9% -$1Mvs FY2024 (Q4)
Gross Profit
$18M
↓-0.3% -$49Kvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
50/100
  • Profitability
    0ROIC -40.2% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 5.07 (above 1.5 = solid)
  • Leverage
    66D/E 0.69 (under 0.5 = conservative)
  • Efficiency
    32Asset Turnover 0.62x (1.0+ = capital-efficient)
  • Growth
    0Revenue YoY -4.9% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin -66.9% · trend +9.3pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$452K
investment in PP&E
Stock buybacks (TTM)
share count reduction
Stock-based comp (TTM)
$21M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$129M
everything owned
Total liabilities
$75M
everything owed
Stockholders' equity
$54M
shareholder claim
Net debt
$-33M
Net cash position ($33M)

Recent performance · 29 quarters

Revenue↓-4.9% -$1M
$23M
Net Income↑+1.3% +$187K
$-14M
Free Cash Flow↑+88.3% +$98K
$-13K
Operating Margin↑+2.4pts
-66.9%

Drill down